Valuation: IXICO plc

Market Cap 17.99M 24.02M 21M 19.3M 34.12M 2.29B 34.64M 232M 90.07M 1.12B 90.17M 88.23M 3.87B P/E 2026 *
-5.16x
P/E 2027 * -6.35x
Enterprise Value 8.39M 11.2M 9.79M 9M 15.91M 1.07B 16.15M 108M 42M 524M 42.05M 41.15M 1.81B EV / Sales 2026 *
1.12x
EV / Sales 2027 * 1.37x
Free-Float
89.25%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 24.04M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 25.19B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average -3.38%+5.57%+79.92%+120.30% 26.95B
Weighted average by Cap. +2.04%+6.10%+91.87%+139.22%

Financials

2026 *2027 *
Net sales 7.5M 10.02M 8.76M 8.05M 14.23M 954M 14.44M 96.6M 37.55M 469M 37.59M 36.79M 1.62B 9M 12.02M 10.51M 9.66M 17.07M 1.14B 17.33M 116M 45.06M 562M 45.11M 44.14M 1.94B
Net income -2.4M -3.2M -2.8M -2.57M -4.55M -305M -4.62M -30.91M -12.02M -150M -12.03M -11.77M -517M -2.8M -3.74M -3.27M -3M -5.31M -356M -5.39M -36.06M -14.02M -175M -14.03M -13.73M -603M
Net Debt -9.6M -12.82M -11.21M -10.3M -18.21M -1.22B -18.48M -124M -48.07M -600M -48.12M -47.09M -2.07B -5.7M -7.61M -6.65M -6.12M -10.81M -725M -10.98M -73.41M -28.54M -356M -28.57M -27.96M -1.23B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0825GBP
Average target price
0.2600GBP
Spread / Average Target
+215.15%

Annual profits - Rate of surprise